{{ mc.sd.lang | uppercase }}
Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti)
Milan Thorel ZooParc de Beauval and Beauval Nature
Alejandro Cabezas-Cruz Ecole Nationale Vétérinaire d'Alfort
Antoine Leclerc ZooParc de Beauval and Beauval Nature
Veronica Risco-Castillo Université Paris-Est
Luis G Bermúdez-Humarán Université Paris-Saclay
José de la Fuente Instituto de Investigación en Recursos Cinegéticos / Oklahoma State University
Alejandra Wu-Chuang Ecole Nationale Vétérinaire d'Alfort
Dasiel Obregon University of Guelph
Jean-Baptiste Delaye CHU de Tours
Guillaume Desoubeaux CHU de Tours / Université de Tours
Yannick Ruel ADVETIA Veterinary Hospital Center
Hugues Gaillot ADVETIA Veterinary Hospital Center
Adnan Hodžić University of Veterinary Medicine Vienna
Mouna Naila Azzouni Ecole Nationale Vétérinaire d'Alfort
Lourdes Mateos-Hernandez Ecole Nationale Vétérinaire d'Alfort
Baptiste Mulot ZooParc de Beauval and Beauval Nature
Frontiers Media Sa
Aspergillosis is a fungal infection caused mainly by Aspergillus fumigatus that often results in respiratory disease in birds. Aspergillosis is a major cause of morbidity and mortality in captive-bred penguin species. Currently, there is no registered vaccine to prevent aspergillosis. Recent research demonstrated that oral administration of gram-negative bacteria expressing high levels of galactose-α-1,3-galactose (α-Gal) modulates anti-α-Gal immunity and protects turkeys from clinical aspergillosis caused by experimental A. fumigatus infection. The role of anti-α-Gal immunity in penguins has not been studied. Here, we tested the distribution of α-1,3-galactosyltransferase (α1,3GT) genes in the fecal microbiome of Humboldt penguins (Spheniscus humboldti). The occurrence of natural anti-α-Gal antibodies (Abs) in sera and eggs of healthy Humboldt penguins was also assessed. A trial was then conducted to test whether oral administration of Escherichia coli Nissle, expressing high α-Gal levels, modulates anti-α-Gal immunity in a colony of Humboldt penguins. Animals in the vaccination and placebo groups were evaluated before the trial and followed for one year for aspergillosis detection using a diagnostic panel including computed tomography scans, capillary zone electrophoresis, 3-hydroxybutyrate levels, and anti-A. fumigatus Abs. Anti-α-Gal Abs were detected in sera (IgM and IgY) and eggs (IgY) of healthy penguins. Microbiota analysis and functional predictions revealed the presence of α1,3GT genes in the microbiota of Humboldt penguins and other penguin species. A strong decrease in anti-α-Gal IgM levels was observed in all animals in the placebo group three months after vaccination protocol. This decrease was not observed in E. coli Nissle-treated penguins. After the vaccination protocol, we found a positive correlation between anti-E. coli IgY and anti-α-Gal IgY in the E. coli Nissle group, suggesting a correlation between the presence of the bacteria and these Abs. During the study period, three penguins exhibited respiratory signs consistent with aspergillosis. Two were from the placebo group whose symptoms resolved with specific treatments, while a single vaccinated individual developed fatal respiratory aspergillosis eight months after the trial. We conclude that E. coli Nissle represents a safe potential probiotic with a protective effect against aspergillosis in Humboldt penguins that deserves to be further explored for therapeutic uses in these animals.
Englisch
2022
Dieses Werk bzw. dieser Inhalt steht unter einer
CC BY 4.0 - Creative Commons Namensnennung 4.0 International Lizenz.
CC BY 4.0 International
http://creativecommons.org/licenses/by/4.0/
Plasma-Protein Electrophoresis; Alpha-Gal; Computed-Tomography; Respiratory System; Psittacine Birds; Pygoscelis-Papua; Immune-Response; Antibodies; Diagnosis; Demersus